Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy
- PMID: 32583973
- PMCID: PMC7433843
- DOI: 10.1002/cam4.3200
Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy
Abstract
Background: Conflicting results has been reported regard osteoporosis and fractures in patients with Differentiated Thyroid Cancer (DTC). Our objective was to evaluate the long-term effects of TSH suppression therapy with Levothyroxine (LT4) on trabecular bone score (TBS) and bone mineral density (BMD) in females with DTC after thyroidectomy.
Methods: About 145 women with resected DTC and receiving long-term TSH therapy, were stratified according to the degree of TSH suppression. Mean duration of follow-up was 12.3 ± 6.1 years. BMD and TBS, were assessed using dual-energy X-ray absorptiometry (DXA) and TBS iNsight (Med-Imaps), at baseline (1-3 months after surgery) and at the final study visit.
Results: In patients stratified by duration of TSH suppression therapy (Group I, 5-10 years; Group II, >10 years), slight increases from baseline TSH levels were observed. Significant decreases in LS-BMD and FN-BMD were seen in patients after >10 years. TBS values were lower in Groups I (1.289 ± 0.122) and II (1.259 ± 0.129) compared with baseline values (P = .0001, both groups). Regarding the degree of TSH suppression, TBS was significantly reduced in those with TSH < 0.1 µU/mL (P = .0086), and not in patients with TSH suppression of 0.1.-0.5 or >0.5 µU/mL.
Conclusions: We found deterioration of trabecular structure in patients with DTC and TSH suppression therapy below 0.1 µU/mL and after 5-10 years of follow-up. Significant changes in BMD according to TSH levels were not observed. Trabecular Bone Score is a useful technique for identifying thyroid cancer patients with risk of bone deterioration.
Keywords: bone mineral density; differentiated thyroid carcinoma; thyrotropin suppressive therapy; trabecular bone score.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no conflicts of interest have nothing to disclose.
Figures


Similar articles
-
Application and prospect of trabecular bone score in differentiated thyroid cancer patients receiving thyrotropin suppression therapy.Front Endocrinol (Lausanne). 2022 Oct 12;13:1004962. doi: 10.3389/fendo.2022.1004962. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36313757 Free PMC article. Review.
-
Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.J Endocrinol Invest. 2021 Oct;44(10):2295-2305. doi: 10.1007/s40618-021-01537-0. Epub 2021 Mar 17. J Endocrinol Invest. 2021. PMID: 33730348
-
Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.Endocrine. 2018 Oct;62(1):166-173. doi: 10.1007/s12020-018-1671-8. Epub 2018 Jul 16. Endocrine. 2018. PMID: 30014437
-
The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma.J Clin Endocrinol Metab. 2017 Jan 1;102(1):78-85. doi: 10.1210/jc.2016-2740. J Clin Endocrinol Metab. 2017. PMID: 27754806
-
Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis.J Clin Endocrinol Metab. 2021 Nov 19;106(12):3655-3667. doi: 10.1210/clinem/dgab539. J Clin Endocrinol Metab. 2021. PMID: 34302730
Cited by
-
Tailoring TSH suppression in differentiated thyroid carcinoma: evidence, controversies, and future directions.Endocrine. 2025 Jul;89(1):1-19. doi: 10.1007/s12020-025-04223-w. Epub 2025 Apr 9. Endocrine. 2025. PMID: 40199841 Review.
-
Application and prospect of trabecular bone score in differentiated thyroid cancer patients receiving thyrotropin suppression therapy.Front Endocrinol (Lausanne). 2022 Oct 12;13:1004962. doi: 10.3389/fendo.2022.1004962. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36313757 Free PMC article. Review.
-
Comparison of Bone Mineral Density and Trabecular Bone Score in Patients with and without Vertebral Fractures and Differentiated Thyroid Cancer with Long-Term Serum Thyrotrophin-Suppressed Therapy.Diagnostics (Basel). 2024 Apr 23;14(9):868. doi: 10.3390/diagnostics14090868. Diagnostics (Basel). 2024. PMID: 38732282 Free PMC article.
-
Application of the Trabecular Bone Score in Clinical Practice.J Bone Metab. 2021 May;28(2):101-113. doi: 10.11005/jbm.2021.28.2.101. Epub 2021 May 31. J Bone Metab. 2021. PMID: 34130362 Free PMC article.
-
Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association.Endocrinol Metab (Seoul). 2023 Apr;38(2):175-189. doi: 10.3803/EnM.2023.1701. Epub 2023 Apr 27. Endocrinol Metab (Seoul). 2023. PMID: 37150514 Free PMC article. Review.
References
-
- Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States 1988–2005. Cancer. 2009;115:3801‐3807. - PubMed
-
- Freudenthal B, Williams GR. Thyroid stimulating hormone suppression in the long‐term follow‐up of differentiated thyroid cáncer. Clin Oncol. 2017;29:325‐328. - PubMed
-
- Haugen BR, Alexander EK, Bible KC, et al. 2016 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133. - PMC - PubMed
-
- McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34:554‐564. - PubMed
-
- Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16:1229‐1234. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous